Coordinating center for the NCI small cell lung cancer research consortium

NCI 小细胞肺癌研究联盟协调中心

• 批准号: 10091407
• 负责人: Charles M. Rudin
• 金额: $ 107.12万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-02-20 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10091407
• 关键词: Acceleration; Address; Administrative Coordination; Animal Model; Bioinformatics; Biological; Biological Models; Biological Specimen database; Biology; Biometry; CRISPR/Cas technology; Cancer Biology; Cancer Research Project; Cancer cell line; Catalogs; Cell Line; Chemoresistance; Clinical; Collection; Communication; Complement; Complex; Country; Data; Data Analyses; Databases; Development; Diagnosis; Disease; Early Diagnosis; Educational workshop; Epigenetic Process; Fostering; Funding; Funding Opportunities; Gene Expression; Generations; Genetic; Genetic Databases; Genetically Engineered Mouse; Goals; Grant; Health Insurance Portability and Accountability Act; Human; In Vitro; Individual; Leadership; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Mentors; Modeling; NIH Program Announcements; Neoplasm Circulating Cells; Patients; Pre-Clinical Model; Prevention; Principal Investigator; Recording of previous events; Reporting; Research; Research Personnel; Research Priority; Resource Sharing; Resources; Secure; Societies; Specimen; Suggestion; Sum; Teleconferences; Therapeutic; Therapeutic Human Experimentation; Tissue Microarray; Tissue Sample; Tissues; Translations; Tumor Tissue; Validation; Work; Xenograft Model; anticancer research; cBioPortal; central database; data exchange; data integration; design; embryonic stem cell; experience; human data; improved; in vitro Model; in vivo; innovation; interest; laboratory experience; lung small cell carcinoma; meetings; member; mouse model; neoplasm resource; novel; novel therapeutics; patient derived xenograft model; pre-clinical; pre-clinical research; programs; repository; resistance mechanism; response; therapeutic development; therapy resistant; tissue resource; tumor; virtual; web site; Acceleration; Address; Administrative Coordination; Animal Model; Bioinformatics; Biological; Biological Models; Biological Specimen database; Biology; Biometry; CRISPR/Cas technology; Cancer Biology; Cancer Research Project; Cancer cell line; Catalogs; Cell Line; Chemoresistance; Clinical; Collection; Communication; Complement; Complex; Country; Data; Data Analyses; Databases; Development; Diagnosis; Disease; Early Diagnosis; Educational workshop; Epigenetic Process; Fostering; Funding; Funding Opportunities; Gene Expression; Generations; Genetic; Genetic Databases; Genetically Engineered Mouse; Goals; Grant; Health Insurance Portability and Accountability Act; Human; In Vitro; Individual; Leadership; Maintenance; Malignant Neoplasms; Malignant neoplasm of lung; Mentors; Modeling; NIH Program Announcements; Neoplasm Circulating Cells; Patients; Pre-Clinical Model; Prevention; Principal Investigator; Recording of previous events; Reporting; Research; Research Personnel; Research Priority; Resource Sharing; Resources; Secure; Societies; Specimen; Suggestion; Sum; Teleconferences; Therapeutic; Therapeutic Human Experimentation; Tissue Microarray; Tissue Sample; Tissues; Translations; Tumor Tissue; Validation; Work; Xenograft Model; anticancer research; cBioPortal; central database; data exchange; data integration; design; embryonic stem cell; experience; human data; improved; in vitro Model; in vivo; innovation; interest; laboratory experience; lung small cell carcinoma; meetings; member; mouse model; neoplasm resource; novel; novel therapeutics; patient derived xenograft model; pre-clinical; pre-clinical research; programs; repository; resistance mechanism; response; therapeutic development; therapy resistant; tissue resource; tumor; virtual; web site

ABSTRACT The goals of this Coordinating Center include facilitating information exchange among investigators in the NCI Small Cell Lung Cancer (SCLC) Consortium, supporting data integration and data analysis, and serving as a central resource for characterization and distribution of model systems. The leadership of this Center consists of a trio of investigators with deep and long-standing research programs focused on SCLC, with complementary strengths and experience. Charles Rudin, an experienced laboratory and clinical researcher focused on SCLC, who has directed two of the largest lung cancer research programs in the country over the past 13 years, serves as the overall PI of the Center, providing administrative leadership and coordination. John Minna and Tyler Jacks serve as co-leaders of the Center. Dr. Minna has consistently and repeatedly led discovery efforts defining SCLC biology over several decades, and together with his collaborators established nearly all of the SCLC cell lines that have served as the basis for SCLC preclinical research. Dr. Jacks has extensive experience in the development and characterization of innovative genetically engineered mouse models of SCLC and over the past decades has served as the primary mentor of many of the active investigators around the world working on mouse models of SCLC. We bring together additional key investigators and unqiue resources that we believe substantially add to the strengths of the Center. Yu Shir at Vanderbilt has established and directs HIPAA-compliant databases used by several multi- investigator consortia. Nikolaus Schultz’s team developed the cBioPortal and continues to expand and improve this leading platform for analysis and integration of complex –omic level data, supporting many multi- investigator consortia worldwide. Adi Gazdar oversees the cell line resource at UT Southwestern, and will support distribution of these lines to U01 SCLC investigators. Anna Farago and Jeff Engelman at MGH, together with John Poirier and Dr. Rudin at MSK, have established substantial resources of SCLC patient- derived xenografts (PDX) and circulating tumor cell-derived xenografts (CDX) models, which are available for distribution among consortium members. Scott Lowe and Andrea Ventura offer highly innovative genetically engineered mouse modeling by CRISPR/Cas9 modulation of embryonic stem cells to rapidly assess genetic contributors to SCLC biology. Afshin Dowlati at Case Western will contribute a large collection of clinically annotated SCLC tissue microarrays representing chemosensitive as well as primary and secondary chemoresistant disease. Together we represent an exceptional team, led by three of the most widely recognized and established investigators in SCLC discovery research, with complementary strengths in therapeutic translation, basic biology, and animal modeling. By providing the resources above, and by coordinating frequent data-sharing opportunities and leading annual face-to-face meetings among SCLC investigators, we believe this Center can substantially accellerate progress against this deadly disease.

抽象的 这个协调中心的目标包括促进调查人员之间的信息交流 NCI小细胞肺癌（SCLC）财团，支持数据集成和数据分析，以及 充当模型系统表征和分布的中心资源。领导 中心由三名研究人员组成，该研究人员的研究计划重点是SCLC， 具有完善的优势和经验。查尔斯·鲁丁（Charles Rudin），经验丰富的实验室和临床 研究人员专注于SCLC，后者指导了两个最大的肺癌研究计划 在过去的13年中，国家是该中心的整体PI，提供行政领导和 协调。约翰·米娜（John Minna）和泰勒·杰克（Tyler Jacks）是该中心的共同领导者。 Minna博士始终如一 多次领导了数十年来定义SCLC生物学的发现努力，并与他的 合作者建立了几乎所有SCLC细胞系，这些细胞系已成为SCLC临床前的基础 研究。杰克斯博士在创新的发展和表征方面拥有丰富的经验 SCLC的基因工程鼠标模型以及过去几十年来一直是主要导师 在世界各地的许多活跃研究人员中，正在研究SCLC的小鼠模型。我们聚集在一起 我们认为的其他主要调查人员和不Qiue资源大大增加了优势 中心。范德比尔特（Vanderbilt）的Yu Shir已建立并指导符合HIPAA的数据库 研究人员联盟。尼古拉斯·舒尔茨（Nikolaus Schultz）的团队开发了CBIOPORTAL，并继续扩展和 改善该领先的平台，用于分析和集成复杂的 - 级别数据，以支持许多多种多样的 全球调查员财团。 ADI GAZDAR负责UT西南部的细胞系列资源，并将 支持这些线向U01 SCLC研究人员的分布。 MGH的Anna Farago和Jeff Engelman， 与MSK的John Poirier和Rudin博士一起，已经建立了SCLC患者的大量资源 - 衍生的Xenographictics（PDX）和循环肿瘤细胞衍生的Xenographographics（CDX）模型，可用于 财团成员之间的分布。 Scott Lowe和Andrea Ventura提供高度创新的 通过CRISPR/CAS9调制胚胎干细胞的工程小鼠建模，以快速评估通用 SCLC生物学的贡献者。 Case Western的Afshin Dowlati将在临床上贡献大量 带注释的SCLC组织微阵列，代表化学敏感性以及原发性和次级 化学抗病。我们共同代表了一个杰出团队，由三个最广泛的领导 在SCLC发现研究领域认可并建立了研究人员，具有完整的优势 治疗翻译，基本生物学和动物建模。通过提供上面的资源以及 在SCLC之间进行经常发起数据共享机会并在年度面对面会议上进行协调 调查人员，我们认为该中心可以基本上加速这种致命疾病的进展。